Cyclerion Therapeutics (Cyclerion Therapeutics) EV-to-Revenue : (As of May. 24, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Cyclerion Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cyclerion Therapeutics's enterprise value is $1.08 Mil. Cyclerion Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Cyclerion Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Cyclerion Therapeutics's EV-to-Revenue or its related term are showing as below:

During the past 7 years, the highest EV-to-Revenue of Cyclerion Therapeutics was 203.09. The lowest was -37.93. And the median was 16.26.

CYCN's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.12
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-24), Cyclerion Therapeutics's stock price is $2.96. Cyclerion Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Therefore, Cyclerion Therapeutics's PS Ratio for today is .

Cyclerion Therapeutics EV-to-Revenue Historical Data

The historical data trend for Cyclerion Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclerion Therapeutics EV-to-Revenue Chart

Cyclerion Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

12.00

41.60

6.24

51.09

Cyclerion Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															162.73	-	-	-	-

Competitive Comparison of Cyclerion Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Cyclerion Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyclerion Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclerion Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cyclerion Therapeutics's EV-to-Revenue falls into.

Cyclerion Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Cyclerion Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	1.078	/	0
	=

Cyclerion Therapeutics's current Enterprise Value is $1.08 Mil.
Cyclerion Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Cyclerion Therapeutics (NAS:CYCN) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Cyclerion Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	2.96	/	0
	=

Cyclerion Therapeutics's share price for today is $2.96.
Cyclerion Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

Cyclerion Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cyclerion Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclerion Therapeutics (Cyclerion Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclerion Therapeutics Inc (NAS:CYCN) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 First Street, 18th Floor, Cambridge, MA, USA, 02142

Website

https://www.cyclerion.com

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Executives

Terrance Mcguire	director	C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Steven Hyman	director	C/O VOYAGER THERAPEUTICS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Andreas Busch	officer: Chief Scientific Officer	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
George H Conrades	director	500 TECHNOLOGY SQUARE, FIFTH FLOOR, CAMBRIDGE MA 02139
Stephanie Lovell	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Ole Isacson	director	CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kevin Churchwell	director	C/O CYCLERION THERAPEUTICS, CAMBRIDGE MA 02142
Michael Mendelsohn	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Peter M Hecht	director, officer: Chief Executive Officer	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Slate Path Capital Lp	10 percent owner	717 5TH AVENUE, 16TH FL., NEW YORK NY 10022
Errol B Desouza	director	215 COLLEGE ROAD, PARAMUS NJ 07652
Anjeza Gjino	officer: Chief Financial Officer	C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Christopher I Wright	officer: Chief Medical Officer	C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Cheryl Gault	officer: Chief Operating Officer	CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Mark G Currie	officer: President and CSO	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142